论文部分内容阅读
目的探讨体外肿瘤药敏试验指导非小细胞肺癌个体化新辅助化疗的临床价值。方法选取江西省肿瘤医院2002—2013年收治的80例非小细胞肺癌患者,随机分为观察组和对照组,每组40例。观察组采用rATP法进行药敏试验,并以药敏试验结果为依据对患者进行新辅助化疗,无敏感药物者采用经验方案化疗;对照组40例患者采用经验方案化疗,比较两组患者的临床疗效、手术完全切除率、病理学总有效率及毒副作用。结果两组患者的治疗总有效率、手术完全切除率比较,差异无统计学意义(P>0.05);观察组患者病理学有效率高于对照组,毒副作用发生率低于对照组,差异有统计学意义(P<0.05)。结论采用体外肿瘤药敏试验指导非小细胞肺癌个体化新辅助化疗,同时结合病理组织学分级评价辅助化疗效果,可有效地提高治疗效果,有较高的应用价值。
Objective To investigate the clinical value of in vitro neoplasms susceptibility testing for individualized neoadjuvant chemotherapy for non-small cell lung cancer. Methods Eighty non-small cell lung cancer patients from 2002 to 2013 in Jiangxi Cancer Hospital were randomly divided into observation group and control group, 40 cases in each group. In the observation group, the drug susceptibility test was conducted by rATP method. Neoadjuvant chemotherapy was performed on the basis of drug susceptibility test results. Empiric regimen chemotherapy was given to the non-sensitive drugs. In the control group, 40 patients were treated with empirical chemotherapy, Efficacy, complete resection rate, total effective pathology and side effects. Results The total effective rate and the complete resection rate of the two groups were not statistically significant (P> 0.05). The effective rate of pathology in the observation group was higher than that of the control group, and the incidence of toxic and side effects was lower than that of the control group Statistical significance (P <0.05). Conclusion Using in vitro antitumor drug sensitivity test to guide individualized neoadjuvant chemotherapy for non-small cell lung cancer and evaluate the effect of adjuvant chemotherapy in combination with histopathological grade can effectively improve the curative effect and have high application value.